Dr. Hershman on Adherence to Longer Hormonal Therapy

Dawn L. Hershman, MD
Published: Thursday, Aug 01, 2013

Dawn L. Hershman, MD, MS, Associate Professor of Medicine and Epidemiology, Leader, Breast Cancer Program, Herbert Irving Comprehensive Cancer Center, Columbia University, discusses the need for adherence with longer hormonal therapy.

Recent studies have further verified the benefit for patients with breast cancer to stay on tamoxifen for 10 years as opposed to 5 years. As a result, the oncology community needs to consider issues related to adherence and compliance.

Researchers have found that at the end of 5 years of tamoxifen, only about 50% of patients take the medication greater than 80% of the time. Researchers also saw that about 25-30% of patients discontinued medication completely, while 25% took it intermittently.

These patients are so far out from their diagnosis, Hershman says, so physicians need to think about how to keep these patients engaged in treatment.
 
Dawn L. Hershman, MD, MS, Associate Professor of Medicine and Epidemiology, Leader, Breast Cancer Program, Herbert Irving Comprehensive Cancer Center, Columbia University, discusses the need for adherence with longer hormonal therapy.

Recent studies have further verified the benefit for patients with breast cancer to stay on tamoxifen for 10 years as opposed to 5 years. As a result, the oncology community needs to consider issues related to adherence and compliance.

Researchers have found that at the end of 5 years of tamoxifen, only about 50% of patients take the medication greater than 80% of the time. Researchers also saw that about 25-30% of patients discontinued medication completely, while 25% took it intermittently.

These patients are so far out from their diagnosis, Hershman says, so physicians need to think about how to keep these patients engaged in treatment.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Community Practice Connections: Oncology Best Practice™ Targeting Cell Cycle Progression: The Latest Advances on CDK4/6 Inhibition in Metastatic Breast CancerOct 31, 20181.0
Publication Bottom Border
Border Publication
x